First-year treatment costs and utilization in people with acute myeloid leukemia (AML) are substantial, whether treated with chemotherapy alone or with alloHCT, according to an analysis involving nearly 1,000 individuals.

Participants were between 50 and 64 years of age and had private insurance. Investigators looked at costs, hospitalizations, inpatient days, and outpatient visit-days, adjusting for age, sex, diagnosis year, region, insurance plan type, Elixhauser Comorbidity Index, and 60-day pre-diagnosis costs. Among the results:

• Average 1-year costs were ~$281,000 for chemotherapy and ~$544,000 for alloHCT.
• The chemotherapy-alone group had an average of 4 hospitalizations, ~53 inpatient days, and ~52 outpatient visits within the first year of diagnosis.
• Those receiving alloHCT averaged 5 hospitalizations, ~93 inpatient days, and ~75 outpatient visits.